Spots Global Cancer Trial Database for recurrent childhood acute lymphoblastic leukemia
Every month we try and update this database with for recurrent childhood acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia | NCT00643240 | Leukemia | yttrium Y 90 an... 111In-BU-12 | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | NCT03504644 | B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob... | Laboratory Biom... Venetoclax Vincristine Lip... | 18 Years - | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | NCT00049569 | L1 Childhood Ac... L2 Childhood Ac... Non-T, Non-B Ch... Recurrent Child... T-cell Childhoo... | cytarabine methotrexate vincristine sul... prednisone pegaspargase doxorubicin hyd... imatinib mesyla... cyclophosphamid... etoposide filgrastim leucovorin calc... asparaginase therapeutic hyd... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003735 | Leukemia | topotecan hydro... | - 21 Years | Children's Oncology Group | |
| STI571 in Treating Patients With Recurrent Leukemia | NCT00004932 | Leukemia | imatinib mesyla... | - 21 Years | Children's Oncology Group | |
| Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | NCT00006462 | Leukemia | gemcitabine hyd... | - 21 Years | Children's Oncology Group | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00053131 | Leukemia | filgrastim sargramostim cytarabine mitoxantrone hy... | 15 Years - | Roswell Park Cancer Institute | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia | NCT00002638 | Leukemia | filgrastim sargramostim carmustine cyclophosphamid... cytarabine etoposide peripheral bloo... radiation thera... | 1 Year - 19 Years | National Cancer Institute (NCI) | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia | NCT00002704 | Leukemia | filgrastim asparaginase cyclophosphamid... daunorubicin hy... dexamethasone etoposide leucovorin calc... liposomal cytar... mercaptopurine mesna methotrexate therapeutic hyd... thiotepa vincristine sul... low-LET electro... low-LET photon ... | - 20 Years | National Cancer Institute (NCI) | |
| Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | NCT02847130 | Acute Lymphobla... B-Cell Non-Hodg... Childhood Acute... Childhood Burki... Childhood Neopl... Hematopoietic a... Malignant Solid... Recurrent Child... | Informational I... Interview Medical Chart R... Questionnaire A... | - 20 Years | Children's Oncology Group | |
| Raltitrexed in Treating Children With Refractory Acute Leukemia | NCT00003528 | Recurrent Child... Recurrent Child... | raltitrexed | - 21 Years | National Cancer Institute (NCI) | |
| Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia | NCT00021242 | Leukemia | docetaxel | - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma | NCT00002738 | Leukemia Lymphoma Sarcoma | leucovorin calc... trimetrexate gl... | - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Ex Vivo Drug Sensitivity Testing and Mutation Profiling | NCT03860376 | Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chil... Refractory Chil... Refractory Chil... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... | 1 Day - 21 Years | Florida International University | ||
| Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia | NCT00002704 | Leukemia | filgrastim asparaginase cyclophosphamid... daunorubicin hy... dexamethasone etoposide leucovorin calc... liposomal cytar... mercaptopurine mesna methotrexate therapeutic hyd... thiotepa vincristine sul... low-LET electro... low-LET photon ... | - 20 Years | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Patients Who Have Hematologic Cancer | NCT00004047 | Leukemia Myelodysplastic... | exatecan mesyla... | - | Daiichi Sankyo | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia | NCT00003729 | Leukemia | cytarabine fludarabine pho... idarubicin | - 17 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia | NCT01625143 | B-cell Childhoo... Recurrent Child... Untreated Child... | laboratory biom... | - 21 Years | Children's Oncology Group | |
| DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia | NCT00899366 | Leukemia | microarray anal... mutation analys... immunologic tec... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT01005277 | Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Child... Recurrent Child... Secondary Acute... | Laboratory Biom... | - | Children's Oncology Group | |
| Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT02819804 | B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil... | Dasatinib Laboratory Biom... Nivolumab Pharmacological... | 18 Years - | Northwestern University | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | NCT01858740 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil... | Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra... | - 21 Years | Fred Hutchinson Cancer Center | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | NCT00897325 | Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... | Cytology Specim... Laboratory Biom... | - 30 Years | Children's Oncology Group | |
| Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate | NCT00898404 | B-cell Childhoo... Childhood Acute... Recurrent Child... T-cell Childhoo... | laboratory biom... | - 17 Years | Children's Oncology Group | |
| Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT02819804 | B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil... | Dasatinib Laboratory Biom... Nivolumab Pharmacological... | 18 Years - | Northwestern University | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia | NCT00022737 | Childhood Acute... Recurrent Child... | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide ifosfamide imatinib mesyla... leucovorin calc... mercaptopurine ... methotrexate pegaspargase vincristine sul... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00967057 | Leukemia | asparaginase dexamethasone idarubicin methotrexate mitoxantrone hy... pegaspargase vincristine sul... | 1 Year - 18 Years | National Cancer Institute (NCI) | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia | NCT01625143 | B-cell Childhoo... Recurrent Child... Untreated Child... | laboratory biom... | - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes | NCT00096135 | Leukemia | filgrastim cyclophosphamid... cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine methotrexate pegaspargase therapeutic hyd... vincristine sul... radiation thera... | 18 Months - 29 Years | Children's Oncology Group | |
| Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma | NCT00002738 | Leukemia Lymphoma Sarcoma | leucovorin calc... trimetrexate gl... | - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia | NCT00002912 | Leukemia | etoposide mitoxantrone hy... valspodar | - 21 Years | National Cancer Institute (NCI) | |
| Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00098839 | Recurrent Child... | L-asparaginase doxorubicin hyd... therapeutic hyd... vincristine sul... epratuzumab cytarabine prednisone pegaspargase dexrazoxane hyd... methotrexate etoposide cyclophosphamid... leucovorin calc... filgrastim | 2 Years - 31 Years | Children's Oncology Group | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | NCT00006462 | Leukemia | gemcitabine hyd... | - 21 Years | Children's Oncology Group | |
| Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia | NCT00089349 | Recurrent Child... | alemtuzumab methotrexate mercaptopurine | - 30 Years | National Cancer Institute (NCI) | |
| Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia | NCT00002961 | Leukemia | cyclophosphamid... cyclosporine etoposide methotrexate allogeneic bone... Total Body Irra... Busulfan Mesna Radiation | - 21 Years | Children's Hospital of Philadelphia | |
| Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia | NCT00003933 | Leukemia | laboratory biom... | - 17 Years | Children's Oncology Group | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia | NCT00002961 | Leukemia | cyclophosphamid... cyclosporine etoposide methotrexate allogeneic bone... Total Body Irra... Busulfan Mesna Radiation | - 21 Years | Children's Hospital of Philadelphia | |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes | NCT00096135 | Leukemia | filgrastim cyclophosphamid... cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine methotrexate pegaspargase therapeutic hyd... vincristine sul... radiation thera... | 18 Months - 29 Years | Children's Oncology Group | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | NCT02220985 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra... | - 60 Years | Fred Hutchinson Cancer Center | |
| 506U78 in Treating Patients With Refractory Hematologic Cancer | NCT00002970 | Recurrent Child... Recurrent Child... T-cell Childhoo... | nelarabine methotrexate cytarabine therapeutic hyd... | - 21 Years | National Cancer Institute (NCI) | |
| Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT00873093 | B-cell Adult Ac... B-cell Childhoo... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... T-cell Adult Ac... T-cell Childhoo... | L-asparaginase doxorubicin hyd... therapeutic hyd... vincristine sul... cytarabine prednisone bortezomib pegaspargase methotrexate etoposide phosp... cyclophosphamid... filgrastim leucovorin calc... laboratory biom... High Dose MTX | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT02819804 | B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil... | Dasatinib Laboratory Biom... Nivolumab Pharmacological... | 18 Years - | Northwestern University | |
| Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | NCT00544466 | Leukemia Myelodysplastic... | fludarabine pho... melphalan allogeneic hema... intensity-modul... | 7 Years - | City of Hope Medical Center | |
| Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
| Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia | NCT00643240 | Leukemia | yttrium Y 90 an... 111In-BU-12 | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | NCT01403415 | Childhood B Acu... Childhood T Acu... Mature T-Cell a... Recurrent Child... Recurrent Child... | Dexamethasone Laboratory Biom... Methotrexate Mitoxantrone Hy... Pegaspargase Pharmacological... Temsirolimus Vincristine Sul... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT01445080 | Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea... | Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | NCT00534430 | Leukemia Myelodysplastic... | busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra... | 16 Years - 50 Years | City of Hope Medical Center | |
| Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | NCT00107354 | Leukemia Myelodysplastic... | aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo... | 14 Years - | Fred Hutchinson Cancer Center | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT00079404 | Acute Undiffere... Recurrent Child... Recurrent Child... Secondary Acute... Unspecified Chi... | tanespimycin | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | NCT00882206 | Leukemia Lymphoma | cytarabine decitabine doxorubicin hyd... imatinib mesyla... methotrexate pegaspargase prednisone vincristine sul... vorinostat | 2 Years - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | NCT01858740 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil... | Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra... | - 21 Years | Fred Hutchinson Cancer Center | |
| Bone Marrow Transplantation in Treating Patients With Leukemia | NCT00006451 | Graft Versus Ho... Leukemia Lymphoma | anti-thymocyte ... cyclophosphamid... cyclosporine methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia | NCT01533168 | Leukemia | cytogenetic ana... nucleic acid se... diagnostic labo... laboratory biom... medical chart r... | 1 Year - 30 Years | Children's Oncology Group | |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | NCT02728700 | Adult Hodgkin L... Adult Myelodysp... Blast Phase Chr... Childhood Chron... Childhood Hodgk... Childhood Myelo... Chronic Phase C... Myelofibrosis Primary Myelofi... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Chro... Refractory Non-... | Allogeneic Hema... Laboratory Biom... Mycophenolate M... Sirolimus | 3 Years - 30 Years | Stanford University | |
| Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | NCT03504644 | B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob... | Laboratory Biom... Venetoclax Vincristine Lip... | 18 Years - | Eastern Cooperative Oncology Group | |
| Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia | NCT01540578 | B-cell Childhoo... Childhood Acute... Recurrent Child... | laboratory biom... | - | Children's Oncology Group | |
| Topotecan in Treating Children With Refractory Leukemia | NCT00002705 | Leukemia | topotecan hydro... | - 20 Years | National Cancer Institute (NCI) | |
| BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | NCT00077493 | Leukemia Lymphoma | BL22 immunotoxi... antibody-drug c... immunotoxin the... monoclonal anti... | 6 Months - 24 Years | MedImmune LLC | |
| Aminopterin in Treating Patients With Refractory Leukemia | NCT00003305 | Leukemia | aminopterin leucovorin calc... | - | National Cancer Institute (NCI) | |
| Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation | NCT00002456 | Graft Versus Ho... Leukemia Lymphoma | cyclosporine methotrexate allogeneic bone... | - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia | NCT00020670 | Leukemia | CD 40 | - | Dana-Farber Cancer Institute | |
| Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | NCT00003437 | Leukemia | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone doxorubicin hyd... mercaptopurine methotrexate pegaspargase prednisolone thioguanine vincristine sul... radiation thera... | 1 Year - 18 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
